Extravasation of oxaliplatin (Eloxatin®) -: clinical course

被引:19
|
作者
Baur, M
Kienzer, HR
Rath, T
Dittrich, C
机构
[1] Kaiser Franz Josef Spital, Med Abt Onkol 3, Ludwig Boltzmann Inst Angew Krebsforsch, Vienna, Austria
[2] Univ Vienna, Chirurg Abt, Inst Plast & Rekonstrukt Chirurg, A-1010 Vienna, Austria
来源
ONKOLOGIE | 2000年 / 23卷 / 05期
关键词
oxaliplatin; extravasation; vesicant; tissue necrosis; local reaction;
D O I
10.1159/000027218
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background: Up to now the cytostatic oxaliplatin was classified as nonvesicant. This is the first report on tissue necrosis induced by oxaliplatin extravasation in literature. A clinical course following oxaliplatin extravasation is reported. Case Report: A 52-year-old white female with adenocarcinoma of the colon and hepatic and pulmonary metastases received palliative chemotherapy consisting of oxaliplatin, leucovorin, and 5-fluorouracil. By mistake oxaliplatin infusion extravasated subcutaneously in the left forearm; consequently, a painless red swelling occurred without any sign of further damage of the tissue. The infusion cannula was removed and oxaliplatin was infused into the right median cubital vein at the elbow. Again oxaliplatin extravasated subcutaneously. A severe painful necrotic reaction of the underlying flexor muscles of the right elbow developed, disabling the patient for 2 months, showing red-brown painful swelling, sclerosis of the skin, induration, fixation, and immobilization of the right elbow. Nonsteroidal analgesics and antibiotics were given, and lymphatic drainage and physiotherapy performed as generally accepted polypragmatic unspecific therapeutic procedure. After 2 months, the patient was able to bow and extend the right elbow except for an extension deficit of 20 degrees, pro- and supination became possible again, pain had completely resolved and strength recovered without limitation. Sclerosis of the skin and stiffness of the underlying tissue were slowly subsiding. Conclusion: Oxaliplatin can induce severe necrosis of underlying muscles by extravasation and therefore must be considered as a vesicant. Therefore oxaliplatin should be applied via a central venous access.
引用
收藏
页码:468 / 471
页数:4
相关论文
共 50 条